Tumoren nach Nierentransplantation

The chronic use of immunosuppressive agents to prevent allograft rejection increases the long-term risk of malignancy. With improved management and better outcomes of post-transplant infectious and cardiovascular complications, it is plausible that in the future post-transplant cancer may become the leading cause of death for this population. Many factors are involved in the development of malignancies including previous malignant diseases, genetic predisposition, viruses and the immunosuppression therapy itself. Lowering the amount of immunosuppression as far as possible and consistent tumor screening before and after transplantation are the current recommendations until new forms of immunosuppression or clinically applicable methods for tolerance induction become available.